Browsing by Author "Akdeniz, A"

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report
    (PERGAMON-ELSEVIER SCIENCE LTD) Ozatli, D; Giden, AO; Erkurt, MA; Korkmaz, S; Basci, S; Ulas, T; Turgut, B; Yigenoglu, TN; Hacibekiroglu, T; Basturk, A; Dal, MS; Namdaroglu, S; Hindilerden, F; Hacioglu, SK; Cagliyan, GA; Ilhan, G; Kacmaz, M; Uysal, A; Merter, M; Ekinci, O; Dursun, FE; Tekinalp, A; Demircioglu, S; Sincan, G; Acik, DY; Akdeniz, A; Ucar, MA; Yeral, M; Ciftciler, R; Teke, HU; Umit, EG; Karakus, A; Bilen, Y; Yokus, O; Albayrak, M; Demir, C; Okan, V; Serefhanoglu, S; Karti, S; Ozkurt, ZN; Eser, B; Aydogdu, I; Kuku, I; Cagirgan, S; Sonmez, M; Ozet, G; Altuntas, F
    Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful sub-stances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers per-forming therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications.
  • No Thumbnail Available
    Item
    Acute Myeloid Leukemia in Elderly, Unfit Patients: Analysis of Turkish AML Prospective Registry Database, on Behalf of Acute Leukemia Working Group of Turkish Society of Hematology
    (AMER SOC HEMATOLOGY) Urlu, SM; Seval, GC; Yücel, EE; Mehtap, O; Yenihayat, EM; Polat, MG; Malkan, UY; Ozbalci, D; Kaya, SY; Durusoy, SS; Akdeniz, A; Kirkizlar, O; Dogan, A; Pinar, IE; Kacmaz, M; Ozturk, HBA; Atas, U; Deveci, B; Akat, GK; Guven, ZT; Sevindik, OG; Demirkan, F; Alacacioglu, I; Karakus, V
  • No Thumbnail Available
    Item
    Acquired Hemophilia A In Adults: A Multicenter Study from Turkey
    (SPRINGER INDIA) Davulcu, EA; Demirci, Z; Yilmaz, U; Ar, MC; Teke, HÜ; Karakus, V; Çiftçiler, R; Selim, C; Yavasoglu, I; Durusoy, SS; Okan, V; Akdeniz, A; Yolcu, A; Aydogdu, I; Güney, T; Yilmaz, AF; Sahin, F
    Acquired hemophilia A (AHA) is a rare disease caused by autoantibodies inhibiting factor VIII (FVIII) activity. Although the conditionis usually idiopathic, there may be other underlying diseases. Treatment consists of two steps: treatment of acute bleeding and immunosuppression. In this multicenter study, we aimed to demonstrate the clinical characteristics, management details, and survival of AHA patients in Turkey. Data was collected from eleven centers in Turkey. aPTT, FVIII, FVIII inhibitor, and hemoglobin (HB) levels, mixing test results, and demographics at diagnosis, treatment information, adverse events, bleeding episodes during follow-up, relapses, and outcome were analyzed. Twenty-nine patients were analyzed (58.6% female). No underlying disorder could be detected in 14 patients. The most prevalent etiologies were pregnancy, malignancy and infections. The median FVIII activity and FVIII inhibitor titer at diagnosis were 0.7% (0.0-29.4%) and 32.6 BU (0.6-135.6 BU) respectively. Bleeding was severe in 44.8% of patients. The HB value was significantly lower in patients with severe bleeding. Most of the patients (n = 25, 86.2%) had only one bleeding episode without relapse, three patients (10.3%) had two bleeding episodes, and one patient had more than three bleedings. 21 (75%) patients received hemostatic therapy. The use of recombinant FVIIa was slightly higher than activated prothrombin complex concentrate (15 versus 10 patients). Immunosuppressive treatment was initiated in 26 (93%) patients. Regimens containing steroid, cyclophosphamide, and rituximab in different combinations were the most preferred. The median follow-up period was 13 months (2-156 months). Median overall survival was 154.97 months. Four and six-year survival were 90.9 +/- 0.8% and 77.9 +/- 14.1% respectively. This is a unique study that investigated the demographic characteristics, treatment approaches, and patient survival of AHA in Turkey.
  • No Thumbnail Available
    Item
    Prospective Real-World Outcomes of Acute Myeloid Leukemia
    (AMER SOC HEMATOLOGY) Karakus, V; Iltar, U; Yenihayat, EM; Polat, MG; Celik, S; Malkan, UY; Seval, GC; Dogan, A; Akdeniz, A; Pinar, IE; Ozdalci, D; Ince, I; Erdem, R; Mehtap, O; Kirkizlar, HO; Kacmaz, M; Deveci, B; Aykas, F; Akat, GK; Kaya, SY; Ozturk, HBA; Sevindik, O; Can, F; Cekdemir, D; Aslan, C; Bulbul, H; Guven, ZT; Maral, S; Durusoy, SS; Demirkan, F; Goker, H; Ozkalemkas, F; Keklik, M; Toprak, SK; Yucel, EE; Atas, U; Alacacioglu, I
  • No Thumbnail Available
    Item
    Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
    (GALENOS YAYINCILIK) Tombak, A; Tanrikulu, FP; Durusoy, SS; Dinçyürek, HD; Kaya, E; Ümit, EG; Yavasoglu, I; Mehtap, Ö; Deveci, B; Özcan, MA; Terzi, H; Okay, M; Sayinalp, N; Yilmaz, M; Okan, V; Kizikli, A; Özcan, Ö; Çetin, G; Demircioglu, S; Aydogdu, I; Saydam, G; Davulcu, EA; Ilhan, G; Uçar, MA; Özet, G; Akpinar, S; Turgut, B; Berber, I; Kurtoglu, E; Sönmez, M; Batur, DS; Yildirim, R; Özkocamaz, V; Günes, AK; Sahip, B; Ertop, S; Akay, OM; Bastürk, A; Dogu, MH; Akdeniz, A; Ünal, A; Seyhanli, A; Gürkan, E; Çekdemir, D; Ferhanoglu, B
    Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age +/- standard deviation: 64.6 +/- 10.3 years, 66.9% males) who had received at least one dose of ibrutinib were included in this retrospective multicenter, noninterventional hospital-registry study conducted at 33 centers across Turkey. Data on patient demographics, baseline characteristics, laboratory findings, and leukemia-cell cytogenetics were retrieved. Treatment response, survival outcome including overall survival (OS) and progression-free survival (PFS), and safety data were analyzed. Results: Overall, 36.7% of patients were categorized as Eastern Cooperative Oncology Group (ECOG) class 2-3, while 44.9% were in Rai stage 4. Fluorescence in situ hybridization revealed the presence of del(17p) in 39.8% of the patients. Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. Median duration of therapy was 8.8 months (range: 0.4-58.0 months). The 1-year PFS and OS rates were 82.2% and 84.6%, respectively, while median PFS time was 30.0 (standard error, 95% confidence interval: 5.1, 20.0-40.0) months and median OS time was 37.9 (3.2, 31.5-44.2) months. Treatment response (complete or partial response), PFS time, and OS time were better with 0-2 lines versus 3-7 lines of prior therapy (p<0.001, p=0.001, and p<0.001, respectively), with ECOG class 0-1 versus class 2-3 (p=0.006, p=0.011, and p=0.001, respectively), and with Rai stage 0-2 versus 3-4 (p=0.002, p=0.001, and p=0.002, respectively). No significant difference was noted in treatment response rates or survival outcome with respect to the presence of comorbidity, bulky disease, or del(17p). While 176 adverse events (AEs) were reported in 74 (54.4%) patients, 46 of those 176 AEs were grade 3-4, including pneumonia (n=12), neutropenia (n=11), anemia (n=5), thrombocytopenia (n=5), and fever (n=5). Conclusion: This real-life analysis confirms the favorable efficacy and safety profile of long-term ibrutinib treatment while emphasizing the potential adverse impacts of poorer ECOG performance status, heavy treatment prior to ibrutinib, and advanced Rai stage on patient compliance, treatment response, and survival outcomes.
  • No Thumbnail Available
    Item
    Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study
    (AMER SOC HEMATOLOGY) Tombak, A; Tanrikulu, FP; Durusoy, SS; Gurkan, E; Kaya, E; Umit, EG; Yavasoglu, I; Mehtap, O; Deveci, B; Ozcan, MA; Terzi, H; Okay, M; Sayinalp, N; Yilmaz, M; Okan, V; Kizikli, A; Ozcan, O; Cetin, G; Demircioglu, S; Aydogdu, I; Saydam, G; Davulcu, EA; Ilhan, G; Ucar, MA; Ozet, G; Akpinar, S; Turgut, B; Berber, I; Kurtoglu, E; Sonmez, M; Batur, DS; Yildirim, R; Ozkocaman, V; Gunes, AK; Sahip, B; Ertop, S; Akay, M; Basturk, A; Dogu, MH; Akdeniz, A; Unal, A; Seyhanli, A; Ferhanoglu, B